

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities nor is it calculated to invite any such offer or invitation. In particular, this announcement does not constitute and is not an offer to sell or an invitation or a solicitation of any offer to buy or subscribe for any securities in Hong Kong, the United States of America or elsewhere. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities described herein have not been and will not be registered under the U.S. Securities Act. There will be no public offering of securities in the United States of America or any jurisdiction other than Hong Kong.*

Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from the United States of America or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

FOSUN PHARMA **复星医药**

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock Code: 02196)

PROPOSED SPIN-OFF AND SEPARATE LISTING OF FOSUN ADGENVAX ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE

This announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) pursuant to Practice Note 15.

We refer to the announcement dated 22 January 2026 and the circular dated 4 February 2026 (the “**Circular**”) of the Company regarding the Proposed Spin-off Listing. The Proposed Spin-off Listing had been approved by the Shareholders of the Company at the 2026 first extraordinary general meeting held on 27 February 2026. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

LISTING APPLICATION AND APPLICATION PROOF

The board of directors of the Company are pleased to announce that the Company and its controlling shareholder Fosun International Limited (“**Fosun International**”) have made a joint application to the Hong Kong Stock Exchange pursuant to Practice Note 15 for the approval of the Proposed Spin-off Listing and the Hong Kong Stock Exchange has confirmed that the Company and Fosun International may proceed with the Proposed Spin-off Listing.

The Company was informed that Fosun Adgenvax has submitted a listing application through its joint sponsors to the Hong Kong Stock Exchange on 26 June 2026, to apply for the listing of, and the permission to deal in, the H shares of Fosun Adgenvax on the Main Board of the Hong Kong Stock Exchange.

The application proof, redacted as required, of Fosun Adgenvax's prospectus (the "**Application Proof**") is available for reviewing and downloading on the website of the Hong Kong Stock Exchange (<https://www1.hkexnews.hk/app/appindex.html>).

The Application Proof contains, among other things, certain business and financial information relating to Fosun Adgenvax. Shareholders and potential investors of the Company should note that the Application Proof is in draft form and the information contained in it is incomplete and is subject to change which can be material. The Company shall not have any obligation or liability whatsoever in relation to the contents of the Application Proof.

As disclosed in the Circular, the initial size of the Proposed Issuance of Fosun Adgenvax shall not exceed 25% of the enlarged total share capital of Fosun Adgenvax immediately after the issuance, and the global coordinator(s) or bookrunner(s) shall be granted an over-allotment option not exceeding 15% of the aforementioned initial issuance size. It is estimated that upon completion of the Proposed Spin-off Listing, Fosun Adgenvax will remain as a subsidiary of the Company.

GENERAL

In connection with the Proposed Issuance of Fosun Adgenvax, the price of the H shares of Fosun Adgenvax may be stabilised in accordance with the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). Details of any intended stabilisation and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) will be contained in the prospectus of Fosun Adgenvax, which will be issued in Hong Kong in connection with the Proposed Issuance of Fosun Adgenvax, if the Proposed Spin-off Listing proceeds.

As it is expected that the highest of the applicable percentage ratios (as defined in the Hong Kong Listing Rules) in respect of the Proposed Spin-off Listing shall be less than 5%, the Proposed Spin-off Listing, if it proceeds, will not constitute a notifiable transaction for the Company under the Hong Kong Listing Rules.

The Proposed Spin-off Listing is subject to, among other things, the filing or approval of the CSRC, the Hong Kong Stock Exchange and other relevant regulatory authorities, the market conditions and other factors, and there is no assurance on the aforesaid filing or approval. Therefore, Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisors.

Further announcements will be made by the Company in respect of the Proposed Spin-off Listing as and when appropriate.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
26 June 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

** for identification purposes only*